Cannabinoid Receptor-2 and HIV-Associated Neurocognitive Disorders

Cannabinoids Inhibit HIV-1 Gp120-Mediated Insults in Brain Microvascular Endothelial Cells

(2014) T.-S. Lu et al.   JOURNAL OF IMMUNOLOGY

Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists

(2013) Servio H. Ramirez et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Potential Roles of Microglial Cell Progranulin in HIV-Associated CNS Pathologies and Neurocognitive Impairment

(2013) Hyeon-Sook Suh et al.   Journal of Neuroimmune Pharmacology

HIV-associated neurocognitive disorder

(2013) David B Clifford et al.   LANCET INFECTIOUS DISEASES

Synaptic Dysfunction in the Hippocampus Accompanies Learning and Memory Deficits in Human Immunodeficiency Virus Type-1 Tat Transgenic Mice

(2012) Sylvia Fitting et al.   BIOLOGICAL PSYCHIATRY

The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke

(2012) Alessandro Pini et al.   CURRENT DRUG TARGETS

Activation of Cannabinoid Receptor 2 Attenuates Leukocyte-Endothelial Cell Interactions and Blood-Brain Barrier Dysfunction under Inflammatory Conditions

(2012) S. H. Ramirez et al.   JOURNAL OF NEUROSCIENCE

HIV-Associated Neurological Disorders

(2011) Ik L. Tan et al.   CNS DRUGS

Current understanding of HIV-associated neurocognitive disorders pathogenesis

(2011) Patrick Gannon et al.   CURRENT OPINION IN NEUROLOGY

Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden

(2011) Serena Spudich et al.   JOURNAL OF INFECTIOUS DISEASES

Cannabinoids Inhibit Migration of Microglial-like Cells to the HIV Protein Tat

(2011) Daniel Fraga et al.   Journal of Neuroimmune Pharmacology

Activation of Cannabinoid Type 2 Receptors Inhibits HIV-1 Envelope Glycoprotein gp120-Induced Synapse Loss

(2011) H. J. Kim et al.   MOLECULAR PHARMACOLOGY

Brain cannabinoid CB2 receptors modulate cocaine's actions in mice

(2011) Zheng-Xiong Xi et al.   NATURE NEUROSCIENCE

Editorial NeuroAIDS review

(2010) Paul Shapshak et al.   AIDS

Cannabinoid Administration Attenuates the Progression of Simian Immunodeficiency Virus

(2010) Patricia E. Molina et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Immunoregulation of a CB2 Receptor Agonist in a Murine Model of NeuroAIDS

(2010) Santhi Gorantla et al.   Journal of Neuroimmune Pharmacology

Cannabinoid Inhibition of Macrophage Migration to the Trans-Activating (Tat) Protein of HIV-1 Is Linked to the CB2 Cannabinoid Receptor

(2010) E. S. Raborn et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

HIV-1 neuroimmunity in the era of antiretroviral therapy

(2010) Stephanie D. Kraft-Terry et al.   NEUROBIOLOGY OF DISEASE

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY

A Coat of Many Colors: Neuroimmune Crosstalk in Human Immunodeficiency Virus Infection

(2009) Stephanie D. Kraft-Terry et al.   NEURON

Human Immunodeficiency Virus Protein Tat Induces Synapse Loss via a Reversible Process That Is Distinct from Cell Death

(2008) H. J. Kim et al.   JOURNAL OF NEUROSCIENCE

Cannabinoids Inhibit Network-Driven Synapse Loss between Hippocampal Neurons in Culture

(2008) H. J. Kim et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules

(2008) L. Mestre et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy

(2007) Krishnan Bhaskaran et al.   ANNALS OF NEUROLOGY

CB2receptor-mediated migration of immune cells: it can go either way

(2007) A M Miller et al.   BRITISH JOURNAL OF PHARMACOLOGY